Carsten Reinhardt, M.D. Ph.D
Chief Medical Officer
Dr Carsten Reinhardt joined Immatics Biotechnologies GmbH in October 2009 from Micromet, Inc. (Bethesda, MD), where he was Chief Medical Officer. Before becoming a member of Micromet´s management board in 2005, Dr Reinhardt had global responsibility for Herceptin® development as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland). Prior to his tenure at Roche, Dr Reinhardt was Head of Clinical Development at Fresenius Biotech (Munich, Germany).
Dr Reinhardt brings to Immatics extensive experience in both early and late-stage clinical development. Under his leadership multiple biological compounds were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe with an emphasis in oncology and immunology diseases. Amongst others, he was instrumental in the set-up and oversight of pivotal trials that led to the approval of various anti-cancer drugs including Blincyto® in acute lymphoblastic leukemia (ALL), Removab® in solid tumors as well as various sBLA/MAA for Herceptin® in additional indications (adjuvant breast cancer, gastric cancer).
Prior to joining industry, Dr Reinhardt held medical positions and worked at various academic institutions (University of Tuebingen, Max Planck Institute, Munich) to complete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardt completed his PhD thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany (summa cum laude), and received a Medical Degree in 1994 from the University of Munich, Germany.
Dr Reinhardt is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel. Dr Reinhardt has co-authored more than 30 publications in peer-reviewed journals including Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine.